Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC.

MLA

Le, Xiuning, et al. “Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 24, no. 24, Dec. 2018, pp. 6195–203. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-18-1542.

APA

Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., Tang, M., Sun, H., Elamin, Y., Lacerda, L. C., Lewis, J., Roth, J. A., Swisher, S. G., Lee, J. J., William, W. N., Jr, … Heymach, J. V. (2018). Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 24(24), 6195–6203. https://doi.org/10.1158/1078-0432.CCR-18-1542

Chicago

Le, Xiuning, Sonam Puri, Marcelo V Negrao, Monique B Nilsson, Jacqulyne Robichaux, Theresa Boyle, J Kevin Hicks, et al. 2018. “Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 24 (24): 6195–6203. doi:10.1158/1078-0432.CCR-18-1542.